Black Diamond Therapeutics (BDTX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Black Diamond Therapeutics (BDTX) is expected to announce its Q2 2025 earnings on August 5th, projecting a loss of ($0.26) per share.
• The stock of Black Diamond Therapeutics opened at $2.93, with a market cap of $166.61 million and a fifty-two week high of $6.75.
• Raymond James Financial has upgraded BDTX to an "outperform" rating with a price target of $11.00, while the consensus price target from analysts is $12.80.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

Black Diamond Therapeutics Stock Down 2.6%

NASDAQ:BDTX traded down $0.07 during trading hours on Friday, reaching $2.59. 708,420 shares of the company's stock were exchanged, compared to its average volume of 893,995. The company has a market capitalization of $147.27 million, a P/E ratio of 43.17 and a beta of 2.87. Black Diamond Therapeutics has a 12 month low of $1.20 and a 12 month high of $6.75. The business's 50-day simple moving average is $2.59 and its two-hundred day simple moving average is $2.13.

Hedge Funds Weigh In On Black Diamond Therapeutics

A hedge fund recently raised its stake in Black Diamond Therapeutics stock. Invesco Ltd. boosted its stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 152.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 45,989 shares of the company's stock after buying an additional 27,777 shares during the quarter. Invesco Ltd. owned approximately 0.08% of Black Diamond Therapeutics worth $71,000 at the end of the most recent quarter. 95.47% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Raymond James Financial upgraded shares of Black Diamond Therapeutics to an "outperform" rating and set a $11.00 target price for the company in a report on Tuesday, July 1st. Wall Street Zen upgraded shares of Black Diamond Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $12.80.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.